Biomedical Engineering

生物医学工程

• 批准号: CRC-2021-00210
• 负责人: KazemMoussavi, Zahra
• 金额: $ 14.57万
• 依托单位: University of Manitoba
• 依托单位国家: 加拿大
• 项目类别: Canada Research Chairs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=751528
• 关键词: Biomedical; Engineering

Canada has 6.6 million older adults, more than half a million of whom live with some form of dementia, mostly Alzheimer's Disease; this number is increasing at a higher rate than expected and compared to a decade ago. It is expected to increase even faster due to the COVID-19 pandemic and the COVID related social isolation that is also known to adversely affect an individuals' mental health. Pharmaceutical treatments have so far offered little hope for improving the cognitive state of those impacted. Dementia diagnosis and identifying its subtypes at treatment onset is crucial because Dr. Moussavi's research has shown non-pharmaceutical treatments are more effective if applied at early stages and with personalized treatment strategies. The strategy depends on dementia severity, other concurrent diseases (comorbidities) and dementia type.Dr. Zahra Moussavi' Canada Research Chair Tier 1 program will be using engineering-driven methodologies (including artificial intelligence) for diagnosing dementia subtype at dementia symptom onset, predicting the response of a patient to a particular treatment based on dementia severity, other concurrent diseases (comorbidities) and that dementia type to enable offering an optimized, personalized, effective and non-pharmaceutical treatment. In addition, she has a unique mobile clinical laboratory solution to make all these efforts accessible to all sectors of the society regardless regardless of age, race, gender, and remoteness of the community.Dr. Moussavi's research will unlock some of the mysteries that surround the response of a patient to different treatments and paves the way for more effective personalized treatment options. So far, she has developed accurate methods for predicting which patients will best respond to pulsatile versus electromagnetic therapies.Dr. Moussavi envisions establishing a unique diagnostic and technologically advanced multidimensional, multifaceted, cross-disciplinary integrated treatment center for dementia (and its many subtypes) in Winnipeg that will eventually lead to preventing dementia and enable aging with a healthy brain.

加拿大有660万老年人，其中50多万人患有某种形式的痴呆症，主要是阿尔茨海默氏症；与十年前相比，这一数字的增长速度高于预期。由于新冠肺炎大流行和与新冠肺炎相关的社会孤立，预计增长更快，众所周知，这种社会孤立也会对个人的心理健康产生不利影响。到目前为止，药物治疗对改善受影响者的认知状态几乎没有什么希望。痴呆症的诊断和在治疗开始时确定其亚型至关重要，因为穆萨维博士的研究表明，如果在早期阶段使用非药物治疗并采用个性化的治疗策略，那么非药物治疗会更有效。这一策略取决于痴呆症的严重程度、其他并发疾病(合并症)和痴呆症类型。Zahra Mousavi的加拿大研究主席Tier 1计划将使用工程驱动的方法(包括人工智能)来诊断痴呆症症状开始时的痴呆症亚型，根据痴呆症的严重程度、其他并发疾病(合并症)和痴呆症类型预测患者对特定治疗的反应，从而能够提供优化的、个性化的、有效的和非药物治疗。此外，她拥有独特的移动临床实验室解决方案，使所有这些努力都能为社会所有部门所用，无论年龄、种族、性别和社区的偏远程度。穆萨维的研究将揭开围绕患者对不同治疗方法的反应的一些谜团，并为更有效的个性化治疗选择铺平道路。到目前为止，她已经开发出准确的方法来预测哪些患者对脉搏疗法和电磁疗法的反应最好。穆萨维设想在温尼伯建立一个独特的诊断和技术先进的多维、多方面、跨学科的痴呆症(及其许多亚型)综合治疗中心，最终将导致预防痴呆症并使大脑健康地老化。